Senomyx in brief
Senomyx is an unlisted company in the Diagnostics and Research industry, based in San Diego, USA. It was founded in 1999. In the year to December 2017 it had sales of $29 M.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Senomyx
Senomyx is an American biotechnology company that develops food additives. The company claims to have "reverse engineered" human taste and aroma receptors. It was founded by Lubert Stryer and Paul Nevsky in 1998. On September 17, 2018, private Swiss company Firmenich completed the acquisition of Senomyx.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Senomyx timeline
- 1999
- 🏁
- 2001
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
Events of Senomyx from Wikidata and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Senomyx
- Acquisitions and changes
- Taken over: the company reported a change in control and the delisting of its shares to the SEC on 2 November 2018 (Form 8-K).
Market cap history
Not enough history yet.
Key ratios
- P/E ratio
- —
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- —
- Operating margin
- -4.5%
- Return on equity
- —
- Liabilities / assets
- 32.0%
- Revenue growth
- +27.3%
- R&D / revenue
- 51.2%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2017 | $29M | +27.3% | $-1M | — | — |
| Dec 2016 | $23M | -7.4% | $-11M | — | — |
| Dec 2015 | $25M | -10.1% | $-13M | — | — |
| Dec 2014 | $28M | -5.6% | $-12M | — | — |
| Dec 2013 | $29M | -6.5% | $-12M | — | — |
| Dec 2012 | $31M | -0.8% | $-9M | — | — |
| Dec 2011 | $32M | +9.3% | $-9M | — | — |
| Dec 2010 | $29M | — | $-11M | — | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2017 | $2M | $1M | $1M | $-0.03 | — |
| Dec 2016 | $-12M | $0M | $-12M | $-0.24 | — |
| Dec 2015 | $-8M | $1M | $-9M | $-0.29 | — |
| Dec 2014 | $-14M | $0M | $-14M | $-0.29 | — |
| Dec 2013 | $-10M | $1M | $-10M | $-0.29 | — |
| Dec 2012 | $-12M | $1M | $-14M | $-0.23 | — |
| Dec 2011 | $-14M | $3M | $-17M | $-0.22 | — |
| Dec 2010 | $22M | $1M | $21M | $-0.28 | — |
SEC filings
- Nov 2, 20188-KCurrent reportAcquisition or disposal completed · Listing notice · Change in control · Directors or officers changed · Bylaws amended
- Sep 17, 20188-KCurrent reportMaterial agreement · Other events
- Aug 15, 201810-K/AAnnual report (amended) · period to Dec 2017
- Aug 2, 201810-QQuarterly report · period to Jun 2018
- Aug 2, 20188-KCurrent reportResults of operations
- Jul 19, 20188-KCurrent reportOther events
- May 31, 20188-KCurrent reportShareholder vote
- Apr 26, 201810-QQuarterly report · period to Mar 2018
- Apr 26, 20188-KCurrent reportResults of operations
- Apr 9, 2018DEF 14AProxy statement
- Mar 22, 20188-KCurrent reportDirectors or officers changed
- Mar 8, 201810-KAnnual report · period to Dec 2017
Official filings of Senomyx with the US Securities and Exchange Commission.
Annual results
- Revenue
- $29 M
- Operating income
- $-1 M
- Net income
- —
For year ending December-2017 · source: SEC filing
Balance sheet
- Total assets
- $28 M
- Total liabilities
- $9 M
- Total equity
- $19 M
As of December-2017
Insider trading at Senomyx#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Stephen A. BlockDirector | Tender in a change of control | -1,000 | $1.500 | $2 K | 0 | Form 4 |
| filed | Kent SnyderDirector | Tender in a change of controlindirect | -414,288 | $1.500 | $621 K | 0 | Form 4 |
| filed | Mary Ann GrayDirector | Tender in a change of control | -10,000 | $1.500 | $15 K | 0 | Form 4 |
| filed | Catherine Chai-zon LeeSr. V.P. Gen. Counsel & Sec. | Tender in a change of control | -36,920 | $1.500 | $55 K | 0 | Form 4 |
| filed | John PoyhonenPresident & CEO, Director | Tender in a change of control | -111,469 | $1.500 | $167 K | 0 | Form 4 |
| filed | E. Thomas Erdmann IIIDirector | Tender in a change of control | -500 | $1.500 | $750 | 0 | Form 4 |
| filed | David Carl HumphreyV.P. & Chief Financial Officer | Tender in a change of control | -432,810 | $1.500 | $649 K | 0 | Form 4 |
| filed | Sharon WickerSr VP & Chf Comm Dvlpt Officer | Tender in a change of control | -131,897 | $1.500 | $198 K | 0 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Senomyx scorecard#
Passes 3 of the 9 checks that could be worked out. Fiscal year 2017.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth1 of 5
- ✓Revenue grew in the newest year27.3%Revenue up 27.3% in fiscal 2017.
- ✗Revenue up more than 5% a year over three years2.0%2.0% a year over the three years to fiscal 2017.
- ✗Faster growth over three years than its peers' median2.0%2.0% a year against Diagnostics and Research's median of 3.6% (64 companies).
- ✗Earnings per share grew in the newest year-0.03 vs -0.24Diluted EPS -0.03 in fiscal 2017 against -0.24 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2017.
Profitability1 of 2
- –Profitable in the newest yearNo net income on file.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- ✗Operating margin above its peers' median-4.5%-4.5% against Diagnostics and Research's median of -2.4% (66 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-4.5%-4.5% in fiscal 2017 against -44.1% in 2014.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities4.6×Current ratio 4.58 at the end of fiscal 2017.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2017.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Senomyx: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 | FY 2015to Dec 31, 2015 | FY 2014to Dec 31, 2014 | FY 2013to Dec 31, 2013 | FY 2012to Dec 31, 2012 | FY 2011to Dec 31, 2011 | FY 2010to Dec 31, 2010 | FY 2009to Dec 31, 2009 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 29+27.3%100% | 23−7.4%100% | 25−10.0%100% | 28−5.5%100% | 29−6.5%100% | 31−0.8%100% | 32r31+9.3%100% | 29r29+86.1%100% | 16—100% | |
| Research and development | 15−22.3%51.2% | 19−13.8%83.8% | 22−10.0%90.0% | 25−8.1%90.0% | 27+0.4%92.5% | 27r29−0.4%86.2% | 27r29+1.7%85.9% | 27−5.5%92.3% | 28—182% | |
| Selling, general and administrative | 12+3.3%41.4% | 12−8.5%51.0% | 13+2.2%51.6% | 13+2.4%45.5% | 12+5.7%41.9% | 12+1.0%37.1% | 12—36.4% | — | — | |
| General and administrative | — | — | — | — | — | 12+1.0%37.1% | 12−12.1%36.4% | 13−4.4%45.3% | 14—88.2% | |
| Operating expenses | 31−9.3%105% | 34−10.0%147% | 38−5.7%151% | 40−3.3%144% | 41+1.6%141% | 41+0.4%130% | 40r40+1.4%128% | 40r40−4.8%138% | 42—270% | |
| Operating income | −1.3—−4.5% | −11—−46.7% | −13—−51.0% | −12—−44.1% | −12—−40.7% | −9.3—−29.6% | −8.9—−28.1% | −11—−38.1% | −26—−170% | |
| Other non-operating income (expense) | 0.1−4.1%0.2% | 0.1+73.8%0.3% | 0.0+13.5%0.2% | 0.0+5.7%0.1% | 0.0−47.8%0.1% | 0.1−47.7%0.2% | 0.1−62.2%0.4% | 0.3+63.8%1.2% | 0.2—1.3% | |
| Earnings per share, basic | -0.03—— | -0.24—— | -0.29—— | -0.29—— | -0.29—— | -0.23—— | -0.22—— | -0.28—— | -0.85—— | |
| Earnings per share, diluted | -0.03—— | -0.24—— | -0.29—— | -0.29—— | -0.29—— | -0.23—— | -0.22—— | -0.28—— | -0.85—— | |
| Shares, weighted average (basic) | — | — | — | — | — | — | 40+4.9%— | 38+22.0%— | 31—— | |
| Shares, weighted average (diluted) | 47+5.3%— | 45+1.9%— | 44+3.2%— | 43+4.8%— | 41+1.8%— | 40+1.0%— | 40+4.9%— | 38+22.0%— | 31—— | |
| Balance sheet | ||||||||||
| Cash and cash equivalents | 6.2+73.8%22.6% | 3.6−25.6%15.1% | 4.8+21.6%14.8% | 4.0−64.6%10.4% | 11−27.4%26.9% | 15−3.4%29.0% | 16−24.9%23.6% | 21−15.2%25.1% | 25—— | |
| Short-term investments | 9.6—34.9% | — | — | — | — | — | — | — | — | |
| Receivables | 7.1+33.2%25.8% | 5.4+67.6%22.5% | 3.2+40.3%9.8% | 2.3+7.1%6.0% | 2.1−21.3%5.1% | 2.7+11.0%5.1% | 2.4+57.1%3.6% | 1.5—1.8% | — | |
| Inventory | 1.6−32.4%5.7% | 2.3−4.1%9.8% | 2.4+5.0%7.5% | 2.3+1083%6.1% | 0.2—0.5% | — | — | — | — | |
| Other current assets | 0.5−52.5%1.7% | 1.0+48.9%4.1% | 0.7−33.5%2.0% | 1.0+46.7%2.6% | 0.7r0.9−19.9%1.6% | 0.8+19.7%1.6% | 0.7−61.3%1.0% | 1.8r3.4—2.2% | — | |
| Current assets | 25+19.0%90.7% | 21−28.1%88.5% | 29−9.1%89.8% | 32−3.0%84.3% | 33−17.8%79.7% | 40−28.3%75.7% | 56−5.1%83.1% | 59—70.0% | — | |
| Property, plant and equipment | 2.6−6.2%9.3% | 2.7−18.1%11.5% | 3.3−13.1%10.2% | 3.8−32.2%10.0% | 5.7−28.5%13.6% | 7.9−15.9%14.8% | 9.4−3.0%13.9% | 9.7—11.4% | — | |
| Total assets | 28+16.1%100% | 24−27.0%100% | 33−14.6%100% | 38−8.3%100% | 42−21.9%100% | 53−21.2%100% | 68−20.1%100% | 85—100% | — | |
| Accounts payable | 0.6−46.7%2.1% | 1.1r1.1+207%4.5% | 0.4r0.4−66.9%1.1% | 1.1r1.1+60.5%2.8% | 0.7r0.7+68.7%1.6% | 0.4r0.4+17.3%0.7% | 0.3r6.1−95.4%0.5% | 7.3—8.6% | — | |
| Current liabilities | 5.5−4.4%19.8% | 5.7−40.3%24.1% | 9.6−22.5%29.4% | 12−29.5%32.4% | 18−4.0%42.2% | 18−8.5%34.3% | 20−22.9%29.6% | 26—30.6% | — | |
| Retained earnings | −280—−1013% | −278—−1171% | −267—−821% | −255—−668% | −243—−583% | −231—−433% | −222—−328% | −213—−251% | — | |
| Shareholders' equity | 19+26.8%68.0% | 15−24.2%62.3% | 20−17.1%59.9% | 24+19.7%61.7% | 20−23.5%47.3% | 26−13.4%48.3% | 30−7.6%43.9% | 32+83.8%38.0% | 18—— | |
| Total equity | — | — | — | — | — | — | — | 32—38.0% | — | |
| Total liabilities and equity | 28+16.1%100% | 24−27.0%100% | 33−14.6%100% | 38−8.3%100% | 42−21.9%100% | 53−21.2%100% | 68−20.1%100% | 85—100% | — | |
| Shares outstanding | 48+5.5%— | 45+1.8%— | 45+2.6%— | 43+5.5%— | 41+2.5%— | 40+0.9%— | 40+1.7%— | 39—— | — | |
| Cash-flow statement | ||||||||||
| Share-based compensation | 3.2−28.5%10.8% | 4.4−15.8%19.3% | 5.3−14.7%21.2% | 6.2+53.4%22.3% | 4.0−9.9%13.8% | 4.5−7.0%14.3% | 4.8−2.7%15.2% | 4.9—17.1% | — | |
| Cash from operating activities | 2.0—6.9% | −12—−50.1% | −8.2—−33.1% | −14—−49.3% | −9.7—−33.2% | −12—−39.6% | −14−166%−45.4% | 22—74.8% | −9.4—−60.4% | |
| Capital expenditure | −0.6—−1.9% | −0.1—−0.6% | −0.7—−2.8% | −0.3—−1.2% | −0.6—−2.1% | −1.5—−4.7% | −3.1—−9.7% | −1.0—−3.4% | −0.4—−2.4% | |
| Cash from investing activities | −1.4−116%−4.9% | 9.1+58.3%39.4% | 5.7—23.0% | −3.6−194%−12.8% | 3.8−66.0%12.9% | 11+46.5%35.6% | 7.6—24.1% | −46—−159% | −0.2—−1.6% | |
| Shares issued | 2.1+64.8%7.0% | 1.2−62.9%5.4% | 3.4−66.3%13.5% | 10.0+479%36.0% | 1.7+130%5.9% | 0.7−47.4%2.4% | 1.4−93.0%4.5% | 20+2893%70.7% | 0.7—4.4% | |
| Cash from financing activities | 2.1+64.8%7.0% | 1.2−62.9%5.4% | 3.4−66.3%13.5% | 10.0+479%36.0% | 1.7+130%5.9% | 0.7−47.4%2.4% | 1.4−93.0%4.5% | 20+2893%70.7% | 0.7—4.4% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2018 | Q2 FY2018to Jun 30, 2018 | Q1 FY2018to Mar 31, 2018 | Q4 FY2017to Dec 31, 2017 | Q3 FY2017to Sep 30, 2017 | Q2 FY2017to Jun 30, 2017 | Q1 FY2017to Mar 31, 2017 | Q4 FY2016to Dec 31, 2016 | Q3 FY2016to Sep 30, 2016 | Q2 FY2016to Jun 30, 2016 | Q1 FY2016to Mar 31, 2016 | Q4 FY2015to Dec 31, 2015 | Q3 FY2015to Sep 30, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 26+34.9%100% | 3.3−32.5%100% | 3.1−30.4%100% | 15+255%100% | 5.1−16.0%100% | 4.9−25.8%100% | 4.5−28.5%100% | 4.2−33.0%100% | 6.0−18.6%100% | 6.6—100% | 6.3—100% | 6.3—100% | 7.4—100% | |
| Research and development | 14−17.0%53.8% | 3.5−7.9%107% | 3.5−12.5%113% | 3.6*−20.0%24.1% | 3.6−25.0%71.2% | 3.8−24.0%78.0% | 4.0−20.0%89.6% | 4.5*−18.2%107% | 4.8−15.8%79.7% | 5.0—76.1% | 5.0—80.0% | 5.5*—87.7% | 5.7—77.1% | |
| Selling, general and administrative | 11−7.3%42.2% | 2.5−19.9%77.4% | 2.7−12.1%86.7% | 3.1*+9.6%20.8% | 2.8−5.2%55.2% | 3.2+8.0%65.2% | 3.1+1.0%68.7% | 2.8*−12.8%67.4% | 2.9−15.0%48.9% | 2.9—44.7% | 3.0—48.6% | 3.3*—51.8% | 3.5—46.9% | |
| Operating expenses | 29−9.6%110% | 7.0−9.3%213% | 6.9−12.7%222% | 7.8−1.3%52.1% | 7.2−14.8%143% | 7.7−11.6%158% | 7.9−8.9%177% | 7.9−14.6%188% | 8.5−13.3%141% | 8.7—133% | 8.7—139% | 9.2—147% | 9.8—133% | |
| Operating income | −2.6—−9.7% | −3.7—−113% | −3.8—−122% | 7.1*—47.9% | −2.2—−43.3% | −2.8—−58.3% | −3.4—−77.2% | −3.7*—−87.7% | −2.5—−41.2% | −2.2—−32.8% | −2.4—−39.0% | −3.0*—−47.2% | −2.4—−32.7% | |
| Other non-operating income (expense) | 0.2+152%0.6% | 0.1+400%2.0% | 0.0+267%1.4% | 0.0*+62.5%0.2% | 0.0−5.0%0.4% | 0.0−27.8%0.3% | 0.0−36.8%0.3% | 0.0*0.0%0.4% | 0.0+122%0.3% | 0.0—0.3% | 0.0—0.3% | 0.0*—0.3% | 0.0—0.1% | |
| Earnings per share, basic | -0.06—— | -0.08—— | -0.08—— | 0.15—— | -0.05—— | -0.06—— | -0.07—— | -0.08—— | -0.05—— | -0.05—— | -0.05—— | -0.07—— | -0.05—— | |
| Earnings per share, diluted | -0.06—— | -0.08—— | -0.08—— | 0.15—— | -0.05—— | -0.06—— | -0.07—— | -0.08—— | -0.05—— | -0.05—— | -0.05—— | -0.07—— | -0.05—— | |
| Shares, weighted average (diluted) | 48+1.7%— | 48+1.7%— | 48+4.6%— | — | 48+6.2%— | 48+6.2%— | 46+2.8%— | — | 45+1.7%— | 45—— | 45—— | — | 44—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 4.5—21.0% | 4.5−18.8%21.0% | 10+109%42.4% | 6.2+73.8%22.6% | 3.9+6.6%21.4% | 5.5−3.7%28.4% | 4.9+112%23.0% | 3.6−25.6%15.1% | 3.7−39.6%14.1% | 5.7—20.0% | 2.3—7.7% | 4.8—14.8% | 6.1—17.4% | |
| Short-term investments | 10—47.6% | 10—47.6% | — | 9.6—34.9% | — | — | — | — | — | — | — | — | — | |
| Receivables | 2.2—10.2% | 2.2−22.2%10.2% | 1.8−66.7%7.5% | 7.1+33.2%25.8% | 5.2+9.7%28.3% | 2.8−7.9%14.4% | 5.5+4.2%25.6% | 5.4+67.6%22.5% | 4.7+78.1%18.1% | 3.1—10.7% | 5.3—17.3% | 3.2—9.8% | 2.7—7.6% | |
| Inventory | 1.9—8.8% | 1.9−7.0%8.8% | 1.6−24.5%6.7% | 1.6−32.4%5.7% | 2.1+3.5%11.4% | 2.0−6.4%10.4% | 2.2−6.4%10.1% | 2.3−4.1%9.8% | 2.0−20.4%7.7% | 2.2—7.6% | 2.3—7.6% | 2.4—7.5% | 2.5—7.3% | |
| Other current assets | 0.3—1.5% | 0.3−49.0%1.5% | 0.4−50.7%1.6% | 0.5−52.5%1.7% | 0.7−16.0%3.6% | 0.6+37.1%3.2% | 0.8+31.6%3.8% | 1.0+48.9%4.1% | 0.8−26.0%3.0% | 0.5—1.6% | 0.6—2.0% | 0.7—2.0% | 1.1—3.1% | |
| Current assets | 19—89.1% | 19+14.2%89.1% | 22+17.8%89.9% | 25+19.0%90.7% | 16−32.7%85.5% | 17−34.7%85.8% | 19−31.7%86.6% | 21−28.1%88.5% | 23−23.3%89.0% | 26—89.3% | 27—89.5% | 29—89.8% | 30—87.1% | |
| Property, plant and equipment | 2.3—10.9% | 2.3−15.6%10.9% | 2.5−14.7%10.1% | 2.6−6.2%9.3% | 2.7−7.8%14.5% | 2.8−9.2%14.2% | 2.9−10.5%13.4% | 2.7−18.1%11.5% | 2.9−18.0%11.0% | 3.1—10.7% | 3.2—10.5% | 3.3—10.2% | 3.5—10.1% | |
| Total assets | 21—100% | 21+9.9%100% | 24+13.5%100% | 28+16.1%100% | 18−30.0%100% | 19−32.0%100% | 21−29.4%100% | 24−27.0%100% | 26−25.0%100% | 29—100% | 30—100% | 33—100% | 35—100% | |
| Accounts payable | 3.8—17.8% | 3.8−9.9%17.8% | 3.5−15.9%14.3% | 0.6−46.7%2.1% | 4.1−20.5%22.3% | 4.2−12.4%21.8% | 4.1−1.3%19.3% | 1.1r1.1+207%4.5% | 5.1−3.8%19.6% | 4.8—16.9% | 4.2—13.8% | 0.4r0.4—1.1% | 5.3—15.3% | |
| Current liabilities | 4.4—20.5% | 4.4−1.7%20.5% | 4.0−7.4%16.6% | 5.5−4.4%19.8% | 4.3−23.4%23.5% | 4.5−41.4%22.9% | 4.4−47.3%20.3% | 5.7−40.3%24.1% | 5.6−44.9%21.5% | 7.6—26.6% | 8.3—27.2% | 9.6—29.4% | 10—29.2% | |
| Retained earnings | −286—−1335% | −286—−1335% | −282—−1156% | −280—−1013% | −287—−1567% | −285—−1462% | −282—−1311% | −278—−1171% | −275—−1051% | −272—−951% | −270—−886% | −267—−821% | −265—−760% | |
| Shareholders' equity | 14—65.7% | 14+15.7%65.7% | 17+22.0%70.5% | 19+26.8%68.0% | 11−36.7%59.3% | 12−32.3%62.4% | 14−25.5%65.5% | 15−24.2%62.3% | 17−18.2%65.7% | 18—62.7% | 19—62.1% | 20—59.9% | 21—60.3% | |
| Total liabilities and equity | 21—100% | 21+9.9%100% | 24+13.5%100% | 28+16.1%100% | 18−30.0%100% | 19−32.0%100% | 21−29.4%100% | 24−27.0%100% | 26−25.0%100% | 29—100% | 30—100% | 33—100% | 35—100% | |
| Shares outstanding | 48—— | 48+1.7%— | 48+1.7%— | 48+5.5%— | 48+6.2%— | 48+6.1%— | 48+6.2%— | 45+1.8%— | 45+1.2%— | 45—— | 45—— | 45—— | 44—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 2.5−34.7%9.5% | 0.5−45.9%14.8% | 0.5−32.7%17.2% | 0.7*−28.9%5.0% | 0.7−32.7%14.5% | 0.9−21.9%18.4% | 0.8−31.0%17.8% | 1.0*−21.7%25.0% | 1.1−17.2%18.1% | 1.1—17.5% | 1.2—18.4% | 1.3*—21.4% | 1.3—17.8% | |
| Cash from operating activities | — | −3.4*−364%−102% | 2.0—63.4% | — | −3.5*—−69.7% | 1.3*+45.4%26.1% | −4.2—−94.5% | −3.3*—−79.0% | −4.6*—−77.0% | 0.9*—13.3% | −4.5—−71.6% | −2.3*—−36.2% | −1.2*—−16.5% | |
| Capital expenditure | −0.3—−1.2% | −0.1*—−2.1% | −0.0—−1.1% | −0.1*—−0.7% | −0.1*—−2.3% | −0.2*—−3.8% | −0.2—−3.4% | −0.0*—−0.8% | −0.1*—−0.9% | −0.0*—−0.2% | −0.0—−0.7% | −0.1*—−0.8% | −0.0*—−0.6% | |
| Cash from investing activities | — | −2.5*—−76.2% | 1.9−45.0%60.2% | — | 1.8*−10.1%35.3% | −0.7*−128%−14.2% | 3.4+150%76.1% | 3.2*+365%76.5% | 2.0*+134%33.0% | 2.5*—38.3% | 1.4—21.7% | 0.7*—11.0% | 0.9*—11.5% | |
| Shares issued | 0.2−94.5%0.6% | 0.0*+1200%0.4% | 0.3−87.8%8.6% | −0.3*−1447%−1.7% | 0.1*−77.7%2.6% | 0.0*−93.8%0.0% | 2.2+247%48.8% | 0.0*−94.1%0.5% | 0.6*−62.5%9.7% | 0.0*—0.2% | 0.6—10.0% | 0.3*—5.2% | 1.6*—21.0% | |
| Cash from financing activities | — | 0.0*+1200%0.4% | 0.3−87.8%8.6% | — | 0.1*−77.7%2.6% | 0.0*−93.8%0.0% | 2.2+247%48.8% | 0.0*−94.1%0.5% | 0.6*−62.5%9.7% | 0.0*—0.2% | 0.6—10.0% | 0.3*—5.2% | 1.6*—21.0% | |
| Change in cash | — | −5.9*−1108%−178% | 4.1+203%132% | — | — | 0.6*—11.9% | 1.4—30.3% | — | — | — | — | — | — | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2018. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Senomyx#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Delisting notice 1 · Restructuring 1 · Taken over and delisted 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 6 · Material agreement 5 · Agreement ended 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 3 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Taken over and delistedChange in controlAcquisition or sale completedDirectors and officersShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Agreement ended | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Directors and officers | 8-K | |
| Material agreementShareholder vote | 8-K/A | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Restructuring | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 2, 2018
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2015 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Senomyx compares in Diagnostics and Research
- Revenue$29 M · higher than 22% of 123
- Revenue growth27.3% · higher than 84% of 89
Peer comparison · Diagnostics and Research
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Senomyx🇺🇸 | — | — | — | +27.3% |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
| Danaher Corporation🇺🇸 | $166.7 B | 38.5× | 16.9% | +2.9% |
| WuXi AppTec Co., Ltd.🇨🇳 | $70.4 B | 25.4× | 42.1% | — |
| Natera, Inc.🇺🇸 | $58.7 B | — | -5.7% | +35.9% |
| Siemens Healthineers AG🇩🇪 | $52.8 B | 22.9× | 8.7% | — |
| Lonza Group AG🇨🇭 | $51.9 B | — | -4.2% | — |
| Agilent Technologies, Inc.🇺🇸 | $48.8 B | 33.9× | 19.5% | +6.7% |
| IQVIA Holdings Inc.🇺🇸 | $45.1 B | 32.4× | 8.1% | +5.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Thermo Fisher Scientific Inc.$253.8 B
- Danaher Corporation$166.7 B
- WuXi AppTec Co., Ltd.$70.4 B
- Natera, Inc.$58.7 B
- Siemens Healthineers AG$52.8 B
- Lonza Group AG$51.9 B
Sources and freshness
- Annual results:
- For year ending December-2017
- Balance sheet:
- As of December-2017
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, Wikidata, Wikipedia, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Senomyx? Verify and update this profile — free
Show Senomyx's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.